SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00096746
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This study will compare the response of subjects who failed a first-line ATV-containing
regimen and who have the 150L-containing virus to subsequent protease inhibitor
(PI)-containing therapy with that of a cohort who has failed a first-line reverse
transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.
NCT00096746 HIV Infection
2 Interventions
Name: LPV/RTV + 2NRTIs
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Type: Drug
Name: LPV/RTV + 2NRTIs
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Type: Drug
Primary Outcomes
Measure: The log10 HIV RNA change from baseline for each cohort. Time: through Week 48
Secondary Outcomes
Measure: Evaluate proportion of patients with plasma HIV RNA <50 copies/mL Time: at Weeks 24, 48, 72, and 96.
Time Perspective: Prospective
Cohort
There is one SNP
SNPs
An Exploratory Study of the Effect of the Atazanavir (ATV) I50L Mutation on Subsequent Treatment Response. --- I50L ---
HPO Nodes